MOORE CAPITAL MANAGEMENT, LP - IBERE PHARMACEUTICALS ownership

IBERE PHARMACEUTICALS's ticker is IBERWS and the CUSIP is G46843119. A total of 37 filers reported holding IBERE PHARMACEUTICALS in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
MOORE CAPITAL MANAGEMENT, LP ownership history of IBERE PHARMACEUTICALS
ValueSharesWeighting
Q4 2022$2,670
-75.7%
150,0000.0%0.00%
Q3 2022$11,000
-8.3%
150,0000.0%0.00%
Q2 2022$12,000
-60.0%
150,0000.0%0.00%
-100.0%
Q1 2022$30,000
-63.0%
150,0000.0%0.00%
-50.0%
Q4 2021$81,000
-10.0%
150,0000.0%0.00%
+100.0%
Q3 2021$90,000
-21.1%
150,0000.0%0.00%
-50.0%
Q2 2021$114,000150,0000.00%
Other shareholders
IBERE PHARMACEUTICALS shareholders Q4 2022
NameSharesValueWeighting ↓
Knott David M Jr 18,000$207,0000.09%
Hartree Partners, LP 642,500$51,400,0000.04%
Radcliffe Capital Management, L.P. 150,000$1,487,0000.04%
TEGEAN CAPITAL MANAGEMENT, LLC 45,710$2,0020.01%
MARSHALL WACE, LLP 224,997$2,231,0000.01%
Ayrton Capital LLC 28,393$2,0000.00%
BOOTHBAY FUND MANAGEMENT, LLC 13,499$134,0000.00%
EHP Funds Inc. 109,569$11,0000.00%
COWEN AND COMPANY, LLC 250,974$21,0000.00%
Alpine Global Management, LLC 61,625$5,0000.00%
View complete list of IBERE PHARMACEUTICALS shareholders